Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages

Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated “cross‐talks” between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advanced science Jg. 9; H. 9; S. e2102620 - n/a
Hauptverfasser:	Yin, Yuan, Liu, Bingxin, Cao, Yulin, Yao, Surui, Liu, Yuhang, Jin, Guoying, Qin, Yan, Chen, Ying, Cui, Kaisa, Zhou, Leyuan, Bian, Zehua, Fei, Bojian, Huang, Shenglin, Huang, Zhaohui
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Germany John Wiley & Sons, Inc 01.03.2022 Wiley
Schlagworte:	Colorectal cancer Cytokines Extracellular vesicles Flow cytometry Genes Immunotherapy Lymphocytes macrophage Medical prognosis MicroRNA MicroRNAs Patients PD‐L1 small extracellular vesicles Survival analysis Tumors PD-L1 macrophage MicroRNA colorectal cancer small extracellular vesicles
ISSN:	2198-3844, 2198-3844
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated “cross‐talks” between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD‐L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD‐L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD‐L1 expression, resulting in increased PD‐L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV‐derived miR‐21‐5p and miR‐200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC‐derived miR‐21‐5p and miR‐200a synergistically induces macrophage M2 like polarization and PD‐L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV‐miRNAs from CRC and targeting PD‐L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti‐PD‐L1 therapy in CRC. A specific PD‐L1+CD206+ macrophage risk subgroup is identified in colorectal cancer, which is induced by tumor‐derived sEV‐miRNAs. This subgroup promotes tumor growth by inducing an immunosuppressive tumor microenvironment. Hence, targeting specific tumor sEV‐miRNAs that regulate PD‐L1 in tumor‐associated macrophages may serve as a novel treatment strategy and a sensitization method for anti‐PD‐L1 therapy in colorectal cancer.
AbstractList	Abstract Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated “cross‐talks” between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD‐L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD‐L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD‐L1 expression, resulting in increased PD‐L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV‐derived miR‐21‐5p and miR‐200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC‐derived miR‐21‐5p and miR‐200a synergistically induces macrophage M2 like polarization and PD‐L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV‐miRNAs from CRC and targeting PD‐L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti‐PD‐L1 therapy in CRC. Tumor-associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated "cross-talks" between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD-L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD-L1 CD206 macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD-L1 expression, resulting in increased PD-L1 CD206 macrophage abundance and decreased T cell activity in CRC TME. sEV-derived miR-21-5p and miR-200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC-derived miR-21-5p and miR-200a synergistically induces macrophage M2 like polarization and PD-L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8 T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV-miRNAs from CRC and targeting PD-L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti-PD-L1 therapy in CRC. Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated “cross‐talks” between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD‐L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD‐L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD‐L1 expression, resulting in increased PD‐L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV‐derived miR‐21‐5p and miR‐200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC‐derived miR‐21‐5p and miR‐200a synergistically induces macrophage M2 like polarization and PD‐L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV‐miRNAs from CRC and targeting PD‐L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti‐PD‐L1 therapy in CRC. A specific PD‐L1+CD206+ macrophage risk subgroup is identified in colorectal cancer, which is induced by tumor‐derived sEV‐miRNAs. This subgroup promotes tumor growth by inducing an immunosuppressive tumor microenvironment. Hence, targeting specific tumor sEV‐miRNAs that regulate PD‐L1 in tumor‐associated macrophages may serve as a novel treatment strategy and a sensitization method for anti‐PD‐L1 therapy in colorectal cancer. Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated “cross‐talks” between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD‐L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD‐L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD‐L1 expression, resulting in increased PD‐L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV‐derived miR‐21‐5p and miR‐200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC‐derived miR‐21‐5p and miR‐200a synergistically induces macrophage M2 like polarization and PD‐L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV‐miRNAs from CRC and targeting PD‐L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti‐PD‐L1 therapy in CRC. Tumor-associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated "cross-talks" between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD-L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD-L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD-L1 expression, resulting in increased PD-L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV-derived miR-21-5p and miR-200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC-derived miR-21-5p and miR-200a synergistically induces macrophage M2 like polarization and PD-L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV-miRNAs from CRC and targeting PD-L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti-PD-L1 therapy in CRC.Tumor-associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed complicated "cross-talks" between cancer cells and macrophages in TME. However, the underlying mechanisms are still poorly elucidated. Here, PD-L1 levels are very low in CRC cells but highly abundant in TAMs, and a specific PD-L1+CD206+ macrophage subpopulation are identified, which is induced by tumor cells and associated with a poor prognosis. Mechanistic investigations reveal that CRC cells can secrete small extracellular vesicles (sEVs) taken up by macrophages that induce M2 like polarization and PD-L1 expression, resulting in increased PD-L1+CD206+ macrophage abundance and decreased T cell activity in CRC TME. sEV-derived miR-21-5p and miR-200a are identified as key signaling molecules mediating the regulatory effects of CRC on macrophages. Further studies reveal that CRC-derived miR-21-5p and miR-200a synergistically induces macrophage M2 like polarization and PD-L1 expression by regulating the PTEN/AKT and SCOS1/STAT1 pathways, resulting in decreased CD8+ T cell activity and increased tumor growth. This study suggests that inhibiting the secretion of specific sEV-miRNAs from CRC and targeting PD-L1 in TAMs may serve as novel methods for CRC treatment as well as a sensitization method for anti-PD-L1 therapy in CRC.
Author	Cui, Kaisa Qin, Yan Cao, Yulin Zhou, Leyuan Yao, Surui Chen, Ying Huang, Shenglin Fei, Bojian Yin, Yuan Jin, Guoying Bian, Zehua Liu, Bingxin Liu, Yuhang Huang, Zhaohui
Author_xml	– sequence: 1 givenname: Yuan surname: Yin fullname: Yin, Yuan organization: Jiangnan University – sequence: 2 givenname: Bingxin surname: Liu fullname: Liu, Bingxin organization: Jiangnan University – sequence: 3 givenname: Yulin surname: Cao fullname: Cao, Yulin organization: Jiangnan University – sequence: 4 givenname: Surui surname: Yao fullname: Yao, Surui organization: Jiangnan University – sequence: 5 givenname: Yuhang surname: Liu fullname: Liu, Yuhang organization: Jiangnan University – sequence: 6 givenname: Guoying surname: Jin fullname: Jin, Guoying organization: Jiangnan University – sequence: 7 givenname: Yan surname: Qin fullname: Qin, Yan organization: Affiliated Hospital of Jiangnan University – sequence: 8 givenname: Ying surname: Chen fullname: Chen, Ying organization: Jiangnan University – sequence: 9 givenname: Kaisa surname: Cui fullname: Cui, Kaisa organization: Jiangnan University – sequence: 10 givenname: Leyuan surname: Zhou fullname: Zhou, Leyuan organization: Affiliated Hospital of Jiangnan University – sequence: 11 givenname: Zehua surname: Bian fullname: Bian, Zehua organization: Jiangnan University – sequence: 12 givenname: Bojian surname: Fei fullname: Fei, Bojian organization: Affiliated Hospital of Jiangnan University – sequence: 13 givenname: Shenglin surname: Huang fullname: Huang, Shenglin email: slhuang@fudan.edu.cn organization: Fudan University – sequence: 14 givenname: Zhaohui orcidid: 0000-0002-0117-9976 surname: Huang fullname: Huang, Zhaohui email: zhaohuihuang@jiangnan.edu.cn organization: Jiangnan University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35037423$$D View this record in MEDLINE/PubMed
BookMark	eNqFkk1vEzEQhi1UREvplSOyxIVLgj92N7vHKAklUhCV-nG1Zr2zwZF3HezdQG79CZz5efwSvE2JUC89eTR-3nfsmXlNTlrXIiFvORtzxsRHqHZhLJjgTGSCvSBnghf5SOZJcvJffEouQtgwxngqJwnPX5FTmbIYCnlGfs-cdR51B5bOoNXo_9z_mqM3O6zodQPW0sXPzoNGa3sLnt5hMNpioFfeNa5DetM3ztNl0_Qt0sUOgnEtLff0dutxHSWdadf0ah5tVzx6xWx4QEx7kMaLaQhOG-hiyS-gvdt-gzWGN-RlDTbgxeN5Tm4_LW5mn0err5fL2XQ10jIv5IizWoOQwDNIOENR1owjliDKos4TXkgAJmXsUDXRGUisM1HF3mR1zKai0vKcLA--lYON2nrTgN8rB0Y9JJxfK_Dd8GlVIauSskaZsSxJcxGrCJnEkCPUHKvo9eHgtfXue4-hU40JQ--gRdcHJQZZmvKCRfT9E3Tjet_Gnw6UyIqJSItIvXuk-rLB6vi8fxOMwPgAxL6F4LE-IpypYUvUsCXquCVRkDwRaNPFKbk2jtnYZ2U_jMX9M0XUdH53LZNUyr_B3tQs
CitedBy_id	crossref_primary_10_1186_s13046_024_02985_1 crossref_primary_10_3390_ijms26020503 crossref_primary_10_4251_wjgo_v17_i6_107382 crossref_primary_10_1038_s41392_023_01452_1 crossref_primary_10_1016_j_cellsig_2023_110901 crossref_primary_10_1038_s41598_025_03113_5 crossref_primary_10_1186_s12935_023_02980_0 crossref_primary_10_1007_s00432_022_04432_0 crossref_primary_10_1002_advs_202408964 crossref_primary_10_1080_02713683_2025_2457102 crossref_primary_10_1007_s00262_025_04047_7 crossref_primary_10_1038_s41467_025_56648_6 crossref_primary_10_1007_s12094_025_03990_2 crossref_primary_10_1038_s41388_025_03356_6 crossref_primary_10_3390_ijms23094493 crossref_primary_10_1186_s12951_024_02888_5 crossref_primary_10_3390_app14072930 crossref_primary_10_3892_mco_2025_2866 crossref_primary_10_1186_s12964_024_01669_9 crossref_primary_10_1007_s00432_024_06022_8 crossref_primary_10_1016_j_biopha_2022_113618 crossref_primary_10_1097_MD_0000000000041379 crossref_primary_10_1007_s00262_024_03865_5 crossref_primary_10_3389_fcell_2023_1225965 crossref_primary_10_3389_fimmu_2024_1362709 crossref_primary_10_3892_ijo_2023_5594 crossref_primary_10_3390_cancers15245795 crossref_primary_10_3389_fimmu_2025_1581964 crossref_primary_10_1186_s12964_024_01473_5 crossref_primary_10_1038_s41392_025_02124_y crossref_primary_10_1186_s12967_024_05963_5 crossref_primary_10_1002_advs_202202993 crossref_primary_10_1186_s13578_022_00823_5 crossref_primary_10_3390_cancers14215450 crossref_primary_10_1007_s12094_022_02932_6 crossref_primary_10_1016_j_cellsig_2024_111263 crossref_primary_10_1096_fj_202402757RR crossref_primary_10_1186_s12935_024_03293_6 crossref_primary_10_32604_biocell_2023_025603 crossref_primary_10_1016_j_phrs_2025_107668 crossref_primary_10_1038_s41416_025_02955_0 crossref_primary_10_1186_s12575_025_00297_y crossref_primary_10_32604_or_2023_043481 crossref_primary_10_3390_cancers16030567 crossref_primary_10_1038_s41388_025_03566_y crossref_primary_10_1007_s12672_025_03183_x crossref_primary_10_3389_fonc_2022_969493 crossref_primary_10_1186_s12967_024_05267_8 crossref_primary_10_3390_cancers15041107 crossref_primary_10_1016_j_intimp_2024_113261 crossref_primary_10_1186_s13046_024_03235_0 crossref_primary_10_1007_s12672_024_01322_4 crossref_primary_10_3390_cancers15123222 crossref_primary_10_3389_fimmu_2025_1537631 crossref_primary_10_1038_s41598_024_61076_5 crossref_primary_10_1038_s41598_024_82331_9 crossref_primary_10_3390_cancers14205121 crossref_primary_10_1080_15384047_2023_2226418 crossref_primary_10_1038_s41388_025_03497_8 crossref_primary_10_1038_s41392_022_00922_2 crossref_primary_10_1186_s13578_024_01201_z crossref_primary_10_3389_fimmu_2024_1385875 crossref_primary_10_1002_mco2_70372 crossref_primary_10_1002_jcp_30906 crossref_primary_10_1007_s00210_025_04219_3 crossref_primary_10_47184_tev_2025_01_05 crossref_primary_10_1007_s11033_024_10157_9 crossref_primary_10_1002_advs_202309298 crossref_primary_10_1039_D4NR01497A crossref_primary_10_1111_imm_13853 crossref_primary_10_1186_s40001_025_03056_7 crossref_primary_10_1111_cpr_70065 crossref_primary_10_1371_journal_pone_0311212 crossref_primary_10_1097_CAD_0000000000001753 crossref_primary_10_1080_21645515_2025_2512656 crossref_primary_10_1111_cbdd_14330 crossref_primary_10_3390_biomedicines13061356 crossref_primary_10_1016_j_jconrel_2023_11_013 crossref_primary_10_1002_jev2_12427 crossref_primary_10_1186_s12951_024_02863_0 crossref_primary_10_3389_fimmu_2023_1147710 crossref_primary_10_2217_crc_2022_0012 crossref_primary_10_1002_advs_202417357 crossref_primary_10_1038_s41423_022_00926_6 crossref_primary_10_3389_fimmu_2023_1265818 crossref_primary_10_1016_j_lfs_2025_123599 crossref_primary_10_3389_fcell_2025_1611434 crossref_primary_10_3390_cells11132070 crossref_primary_10_1186_s12951_023_01888_1 crossref_primary_10_3389_fimmu_2024_1407449 crossref_primary_10_3390_cancers17132172 crossref_primary_10_1186_s12935_025_03809_8 crossref_primary_10_1186_s12967_025_06732_8 crossref_primary_10_1097_MD_0000000000036480 crossref_primary_10_1002_smll_202412679 crossref_primary_10_3390_ijms24065600 crossref_primary_10_4251_wjgo_v16_i10_4064 crossref_primary_10_1186_s12929_025_01182_2 crossref_primary_10_3389_fimmu_2025_1637144 crossref_primary_10_1002_adtp_202300340 crossref_primary_10_1186_s12967_023_04009_6 crossref_primary_10_1002_adhm_202303430 crossref_primary_10_1093_carcin_bgae058 crossref_primary_10_2174_0113816128374077250410042947 crossref_primary_10_1158_0008_5472_CAN_24_0954 crossref_primary_10_3390_ijms26115336 crossref_primary_10_3389_fimmu_2024_1376962 crossref_primary_10_1111_odi_70065 crossref_primary_10_1007_s12094_024_03691_2 crossref_primary_10_1002_ctm2_1591 crossref_primary_10_1186_s12943_025_02258_1 crossref_primary_10_3390_ijms26115332 crossref_primary_10_3389_fimmu_2025_1679537 crossref_primary_10_1186_s12951_025_03326_w
Cites_doi	10.1038/cr.2014.121 10.1158/1078-0432.CCR-06-2073 10.1158/1078-0432.CCR-17-1283 10.1002/hep.30607 10.1038/cti.2016.21 10.1002/cam4.3248 10.1126/science.aau6977 10.1038/nmeth.4185 10.1007/s00280-019-03867-6 10.1016/j.drudis.2019.06.010 10.1038/nature22396 10.1158/2326-6066.CIR-19-0522 10.1038/s41467-018-07810-w 10.1186/s12943-018-0897-7 10.1038/nrclinonc.2016.217 10.1016/j.intimp.2020.106594 10.1038/s41467-018-07767-w 10.3389/fimmu.2020.01731 10.1002/ijc.28736 10.1146/annurev-biochem-013118-111902 10.1186/s12943-019-0981-7 10.3322/caac.21601 10.1016/j.immuni.2018.03.014 10.3324/haematol.2018.197194 10.1016/j.canlet.2020.01.005 10.1186/s13045-020-00991-2 10.1158/1078-0432.CCR-19-1040 10.1186/s40425-019-0770-2 10.1038/s41575-019-0126-x 10.1073/pnas.1612920114 10.1016/j.molcel.2010.06.010 10.1038/nmeth.3337 10.1186/s13059-017-1349-1 10.1038/s41418-019-0460-0 10.1007/s00432-019-02879-2 10.1016/j.soncn.2019.08.011 10.1038/s41467-018-03224-w
ContentType	Journal Article
Copyright	2022 The Authors. Advanced Science published by Wiley‐VCH GmbH 2022 The Authors. Advanced Science published by Wiley-VCH GmbH. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH.
Copyright_xml	– notice: 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH – notice: 2022 The Authors. Advanced Science published by Wiley-VCH GmbH. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH.
DBID	24P AAYXX CITATION NPM 3V. 7XB 88I 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH HCIFZ M2O M2P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 DOA
DOI	10.1002/advs.202102620
DatabaseName	Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central ProQuest Central Student ProQuest Research Library SciTech Premium Collection ProQuest Research Library Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic ProQuest Open Access (no login required) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Science Journals (Alumni Edition) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed Publicly Available Content Database MEDLINE - Academic CrossRef
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General)
EISSN	2198-3844
EndPage	n/a
ExternalDocumentID	oai_doaj_org_article_de0d4bfe36064582ba22346451eaf1ed 35037423 10_1002_advs_202102620 ADVS3453
Genre	article Journal Article
GrantInformation_xml	– fundername: Wuxi Health Committee funderid: BJ2020058 – fundername: High Level Health Talent Project of Jiangsu Province funderid: LGY2019017; LGY2018012 – fundername: National Natural Science Foundation of China funderid: 81672328; 81772636; 81972220 – fundername: Medical Key Professionals Program of Jiangsu Province funderid: AF052141 – fundername: Social Development Project of Jiangsu Province funderid: BE2019632 – fundername: Six Talent Peaks Projects of Jiangsu Province funderid: WSW‐196; WSW‐155 – fundername: Wuxi Taihu Lake Talent Plan, Top Talent – fundername: Wuxi Medical Innovation Team funderid: CXTP003 – fundername: Six Talent Peaks Projects of Jiangsu Province grantid: WSW-196 – fundername: National Natural Science Foundation of China grantid: 81672328 – fundername: National Natural Science Foundation of China grantid: 81772636 – fundername: Six Talent Peaks Projects of Jiangsu Province grantid: WSW-155 – fundername: Wuxi Medical Innovation Team grantid: CXTP003 – fundername: High Level Health Talent Project of Jiangsu Province grantid: LGY2018012 – fundername: Medical Key Professionals Program of Jiangsu Province grantid: AF052141 – fundername: High Level Health Talent Project of Jiangsu Province grantid: LGY2019017 – fundername: Wuxi Health Committee grantid: BJ2020058
GroupedDBID	0R~ 1OC 24P 53G 5VS 88I 8G5 AAFWJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACCMX ACGFS ACUHS ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU AZQEC BCNDV BENPR BPHCQ BRXPI CCPQU DWQXO EBS GNUQQ GODZA GROUPED_DOAJ GUQSH HCIFZ HYE IAO ITC KQ8 M2O M2P O9- OK1 PIMPY PQQKQ PROAC ROL RPM WIN AAMMB AAYXX ADMLS AEFGJ AFFHD AFPKN AGXDD AIDQK AIDYY CITATION EJD IGS PHGZM PHGZT NPM 3V. 7XB 8FK MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c3893-10fca23a16a410e2bf01eeba2b9f84193aa033026d7c6a3ef62d2196f03352dc3
IEDL.DBID	24P
ISSN	2198-3844
IngestDate	Fri Oct 03 12:51:45 EDT 2025 Thu Sep 04 17:49:39 EDT 2025 Wed Aug 13 05:16:31 EDT 2025 Thu Apr 03 06:53:38 EDT 2025 Tue Nov 18 21:52:52 EST 2025 Sat Nov 29 07:24:16 EST 2025 Wed Jan 22 17:21:54 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	PD-L1 macrophage MicroRNA colorectal cancer small extracellular vesicles
Language	English
License	Attribution 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3893-10fca23a16a410e2bf01eeba2b9f84193aa033026d7c6a3ef62d2196f03352dc3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-0117-9976
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadvs.202102620
PMID	35037423
PQID	2642697259
PQPubID	4365299
PageCount	14
ParticipantIDs	doaj_primary_oai_doaj_org_article_de0d4bfe36064582ba22346451eaf1ed proquest_miscellaneous_2645855190 proquest_journals_2642697259 pubmed_primary_35037423 crossref_primary_10_1002_advs_202102620 crossref_citationtrail_10_1002_advs_202102620 wiley_primary_10_1002_advs_202102620_ADVS3453
PublicationCentury	2000
PublicationDate	2022-03-01
PublicationDateYYYYMMDD	2022-03-01
PublicationDate_xml	– month: 03 year: 2022 text: 2022-03-01 day: 01
PublicationDecade	2020
PublicationPlace	Germany
PublicationPlace_xml	– name: Germany – name: Weinheim
PublicationTitle	Advanced science
PublicationTitleAlternate	Adv Sci (Weinh)
PublicationYear	2022
Publisher	John Wiley & Sons, Inc Wiley
Publisher_xml	– name: John Wiley & Sons, Inc – name: Wiley
References	2015; 12 2019; 7 2019; 70 2020; 84 2010; 39 2019; 35 2017; 23 2018; 103 2019; 16 2014; 24 2019; 18 2020; 13 2020; 367 2020; 11 2017; 114 2007; 13 2018; 48 2019; 145 2014; 135 2020; 8 2016; 5 2018; 9 2018; 17 2019; 84 2017; 14 2019; 88 2019; 24 2020; 70 2002; 22 2020; 9 2020; 27 2020; 26 2017; 18 2020; 474 2017; 545 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 Nakayama Y. (e_1_2_9_20_1) 2002; 22 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_1_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1
References_xml	– volume: 13 start-page: 1472 year: 2007 publication-title: Clin. Cancer Res. – volume: 39 start-page: 133 year: 2010 publication-title: Mol. Cell – volume: 12 start-page: 453 year: 2015 publication-title: Nat. Methods – volume: 27 start-page: 1765 year: 2020 publication-title: Cell Death Differ. – volume: 84 start-page: 315 year: 2019 publication-title: Cancer Chemother. Pharmacol. – volume: 26 start-page: 970 year: 2020 publication-title: Clin. Cancer Res. – volume: 22 start-page: 4291 year: 2002 publication-title: Anticancer Res. – volume: 24 start-page: 1164 year: 2014 publication-title: Cell Res. – volume: 35 year: 2019 publication-title: Semin. Oncol. Nurs. – volume: 88 start-page: 487 year: 2019 publication-title: Annu. Rev. Biochem. – volume: 135 start-page: 843 year: 2014 publication-title: Int. J. Cancer – volume: 84 year: 2020 publication-title: Int. Immunopharmacol. – volume: 367 start-page: 6977 year: 2020 publication-title: Science – volume: 23 start-page: 7375 year: 2017 publication-title: Clin. Cancer Res. – volume: 114 start-page: 1117 year: 2017 publication-title: Proc. Natl. Acad. Sci. USA – volume: 14 start-page: 228 year: 2017 publication-title: Nat. Methods – volume: 8 start-page: 255 year: 2020 publication-title: Cancer Immunol. Res. – volume: 13 start-page: 156 year: 2020 publication-title: J. Hematol. Oncol. – volume: 7 start-page: 305 year: 2019 publication-title: J. Immunother. Cancer – volume: 70 start-page: 145 year: 2020 publication-title: Ca Cancer J. Clin. – volume: 9 start-page: 5989 year: 2020 publication-title: Cancer Med. – volume: 17 start-page: 147 year: 2018 publication-title: Mol. Cancer – volume: 145 start-page: 1377 year: 2019 publication-title: J. Cancer Res. Clin. Oncol. – volume: 103 start-page: 1908 year: 2018 publication-title: Haematologica – volume: 18 start-page: 220 year: 2017 publication-title: Genome Biol. – volume: 16 start-page: 361 year: 2019 publication-title: Nat. Rev. Gastroenterol. Hepatol. – volume: 9 start-page: 5395 year: 2018 publication-title: Nat. Commun. – volume: 14 start-page: 399 year: 2017 publication-title: Nat. Rev. Clin. Oncol. – volume: 70 start-page: 241 year: 2019 publication-title: Hepatology – volume: 48 start-page: 434 year: 2018 publication-title: Immunity – volume: 11 start-page: 1731 year: 2020 publication-title: Front. Immunol. – volume: 24 start-page: 2058 year: 2019 publication-title: Drug Discovery Today – volume: 9 start-page: 5361 year: 2018 publication-title: Nat. Commun. – volume: 5 year: 2016 publication-title: Clin. Transl. Immunol. – volume: 18 start-page: 43 year: 2019 publication-title: Mol. Cancer – volume: 474 start-page: 36 year: 2020 publication-title: Cancer Lett. – volume: 545 start-page: 495 year: 2017 publication-title: Nature – volume: 9 start-page: 771 year: 2018 publication-title: Nat. Commun. – ident: e_1_2_9_12_1 doi: 10.1038/cr.2014.121 – ident: e_1_2_9_19_1 doi: 10.1158/1078-0432.CCR-06-2073 – ident: e_1_2_9_4_1 doi: 10.1158/1078-0432.CCR-17-1283 – ident: e_1_2_9_37_1 doi: 10.1002/hep.30607 – ident: e_1_2_9_7_1 doi: 10.1038/cti.2016.21 – volume: 22 start-page: 4291 year: 2002 ident: e_1_2_9_20_1 publication-title: Anticancer Res. – ident: e_1_2_9_31_1 doi: 10.1002/cam4.3248 – ident: e_1_2_9_8_1 doi: 10.1126/science.aau6977 – ident: e_1_2_9_16_1 doi: 10.1038/nmeth.4185 – ident: e_1_2_9_9_1 doi: 10.1007/s00280-019-03867-6 – ident: e_1_2_9_29_1 doi: 10.1016/j.drudis.2019.06.010 – ident: e_1_2_9_5_1 doi: 10.1038/nature22396 – ident: e_1_2_9_30_1 doi: 10.1158/2326-6066.CIR-19-0522 – ident: e_1_2_9_32_1 doi: 10.1038/s41467-018-07810-w – ident: e_1_2_9_11_1 doi: 10.1186/s12943-018-0897-7 – ident: e_1_2_9_21_1 doi: 10.1038/nrclinonc.2016.217 – ident: e_1_2_9_27_1 doi: 10.1016/j.intimp.2020.106594 – ident: e_1_2_9_38_1 doi: 10.1038/s41467-018-07767-w – ident: e_1_2_9_24_1 doi: 10.3389/fimmu.2020.01731 – ident: e_1_2_9_18_1 doi: 10.1002/ijc.28736 – ident: e_1_2_9_10_1 doi: 10.1146/annurev-biochem-013118-111902 – ident: e_1_2_9_33_1 doi: 10.1186/s12943-019-0981-7 – ident: e_1_2_9_1_1 doi: 10.3322/caac.21601 – ident: e_1_2_9_17_1 doi: 10.1016/j.immuni.2018.03.014 – ident: e_1_2_9_22_1 doi: 10.3324/haematol.2018.197194 – ident: e_1_2_9_35_1 doi: 10.1016/j.canlet.2020.01.005 – ident: e_1_2_9_34_1 doi: 10.1186/s13045-020-00991-2 – ident: e_1_2_9_23_1 doi: 10.1158/1078-0432.CCR-19-1040 – ident: e_1_2_9_26_1 doi: 10.1186/s40425-019-0770-2 – ident: e_1_2_9_3_1 doi: 10.1038/s41575-019-0126-x – ident: e_1_2_9_28_1 doi: 10.1073/pnas.1612920114 – ident: e_1_2_9_13_1 doi: 10.1016/j.molcel.2010.06.010 – ident: e_1_2_9_14_1 doi: 10.1038/nmeth.3337 – ident: e_1_2_9_15_1 doi: 10.1186/s13059-017-1349-1 – ident: e_1_2_9_6_1 doi: 10.1038/s41418-019-0460-0 – ident: e_1_2_9_25_1 doi: 10.1007/s00432-019-02879-2 – ident: e_1_2_9_2_1 doi: 10.1016/j.soncn.2019.08.011 – ident: e_1_2_9_36_1 doi: 10.1038/s41467-018-03224-w
SSID	ssj0001537418
Score	2.5880065
Snippet	Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed... Tumor-associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies observed... Abstract Tumor‐associated macrophages (TAMs) are one of the most abundant cell types in colorectal cancer (CRC) tumor microenvironment (TME). Recent studies...
SourceID	doaj proquest pubmed crossref wiley
SourceType	Open Website Aggregation Database Index Database Enrichment Source Publisher
StartPage	e2102620
SubjectTerms	Colorectal cancer Cytokines Extracellular vesicles Flow cytometry Genes Immunotherapy Lymphocytes macrophage Medical prognosis MicroRNA MicroRNAs Patients PD‐L1 small extracellular vesicles Survival analysis Tumors
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQxYELojy3FGQkJOAQ1Y_UyR6hD4EE1UptUW-RH2NRaZutsg_BjZ_AmZ_HL2HGzkaLBOqFazJJbM_DM87MN4y9NEFFEZUvjJOqoNLKwtXBF96qcl-XpgxQpmYT1clJfXExnmy0-qKcsAwPnBduL4AIpYugDSGr1cpZ3NDod5wEGyUEsr7o9WwEU7k-WBMsyxqlUag9G1aEzk0RjqHm3hu7UALr_5uH-afDmnac43vsbu8q8rd5iNvsFrT32XavjHP-ukeMfvOA_cTwf0amC8kPiI3dr-8_DlG2VhD46ZWdTvnR10Vn6ZSe0k75Z5indDg-Sdl4wM-WV7OOf6BiEeDoXdMZGnff-Pl1l5vV4w7HJ4f42o8S39Vnz7b8ss2P4o01o_GTnyw1BvuCpmr-kJ0fH50dvC_6pguFJ98FzXJEPmkrjS2lAOWikAC46m4c6xLdPWuF1riIofLGaohGBbR6Jgqq3gpeP2Jb7ayFJ4xHYWMVJMRS2hIq71w0lcMYyoramrEfsWLNhMb3iOTUGGPaZCxl1RDTmoFpI_ZqoL_OWBz_pHxHPB2oCEM7XUDJanrJam6SrBHbXUtE0ys2fsJQ7W-FQeOIvRhuo0oSB20Ls2WiwSAMXWMcx-MsScNI9D4B_iiNc0-idcNEGnROTjVqzc7_mNFTdkdR9UZKodtlW4tuCc_Ybb9aXM6750mDfgNq8SLp priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgy4FLoTwXCjISEnCImtheJ3tCdLsVSLBa0Rb1Fjl-QKVtsk12V3DjJ3Dm5_FLmHGcABKPA9dkktiab8bjyfgbQh5Lw1zsmI5kkbAIj1ZGRWZ0pBUTIy6kMFb4ZhPpbJadno7nIeHWhLLKzid6R20qjTnyPVi4mRynEK0_X15E2DUK_66GFhqXyRYylYkB2dqfzuZvf2RZRhzpWTq2xpjtKbNBlm7c6Uhs8v3TauRJ-38Xaf4auPqV5_Da_475OtkOMSd90YJkh1yy5Q2yE6y6oU8D9fSzm-TrBHwh-kAQnyAe6m-fvxwASDfW0KNztVjQ6cdVrTDdj_Wr9J1tfF0dnfuyPkuP1-dVTV_hqRNLIUzHZBwtPtGTZd12vYelks4P4LWvE3hXKMMt6VnZPgo3OsTAJ98o7DD2AXxec4ucHE6PJy-j0L0h0hgEgX93oHCuEqlEEltWuDixtlCsGLtMQNyoVMw5aMGkWipunWQG3Kd0MR4DM5rfJoOyKu1dQl2sXGoS60SihE11UTiZFrAZU3Gm5FgPSdRpMdeB2hw7bCzylpSZ5aj1vNf6kDzp5ZctqccfJfcRFL0UknH7C1X9Pg-2nRsbG1E4yyWS_2UM5sgQ5qPEKpdYMyS7HTzy4CHgEz02huRRfxtsGzWoSlutvQzs5iDGhnHcaaHYj4SPkDmIcZi7x-Y_JpJDlHPEwfzu_X0w98lVhgc8fJXdLhms6rV9QK7ozeqsqR8G8_oOrr8yEw priority: 102 providerName: ProQuest
Title	Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadvs.202102620 https://www.ncbi.nlm.nih.gov/pubmed/35037423 https://www.proquest.com/docview/2642697259 https://www.proquest.com/docview/2645855190 https://doaj.org/article/de0d4bfe36064582ba22346451eaf1ed
Volume	9
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: BENPR dateStart: 20141201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: PIMPY dateStart: 20141201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: M2O dateStart: 20141201 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: M2P dateStart: 20141201 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: WIN dateStart: 20140101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2198-3844 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001537418 issn: 2198-3844 databaseCode: 24P dateStart: 20140101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF6hhgMXaHmGlmiRkICDVe8ja-dI01REIsGiLYSTtfbuhkqpUzkPwY2fwJmfxy9hZu24RAIhxGUlZyfrfcyMZ0Y73xDyTBnuQsfzQGWMB5haGWSxyYNcc9kVUkljpS82EY3H8WTSS37J4q_wIZqAG0qG19co4DpbHF6DhmqzRrhtdFkUB6e9xZiIsXgDl8l1lKUrEJ4FK8yBdx2IWMoNcmPID7eH2PoyeQD_31md20as_wqd3Pn_-e-S27UFSl9VLLNHbtjiLtmrZXxBX9RA1C_vke990IyoEYG8j9xR_vj67RhYdm0NPb3UsxkdfF6WGoP_eJuVvrcLf8uOJv6Sn6Vnq8t5SYeYg2IpGO0YmqPZF3p-VdqpLxxWTGlyDMO-YTBWfSm3oBdF9Vfo2PAPvHKksd7YJ9CAi_vk_GRw1n8d1LUcghxNItD2Do5faKa0ZKHlmQuZtZnmWc_FEqxIrUMhYCtMlCstrFPcwJEpF2JSmMnFA7JTzAv7iFAXahcZZp1kWtoozzKnogxcMx3GWvXyNgk255jmNdA51tuYpRVEM09x69Nm69vkeUN_VUF8_JHyCNmioUJobv_DvJymtaSnxoZGZs4KhVCAMYc1cmT6LrPaMWva5GDDVGmtL-AVClOKI_BF2-Rp0w2SjieoCztfeRrw7cDihnk8rJixmYnoIo4QF7B2z3N_WUgKNs-pAGF8_I_0--QWx_wPfwnvgOwsy5V9Qm7m6-XFoux42YM2msQd0joajJN3HR_kgHbE3_oW-lvJcJR8hKcPw_FPXVE7cQ
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VFIlegPIMFFgkEHCwaq-dtXNACJJWjZpEkZqi9mTW-0grpU6wk0Bv_ATO_Ah-FL-EmfUDkHiceuAaT9a79sy3M-uZbwh5whUzrmHS4YnHHCytdJJISUcKFrT8gAdKB7bZRDgcRkdH7dEa-VrVwmBaZYWJFqjVTOIZ-TZs3Iy3Q_DWX83fO9g1Cr-uVi00CrXY1-cfIGTLX_a68H6fMra7M-7sOWVXAUfi5gy4Y2AivvC4CDxXs8S4ntaJYEnbRAH4M0K4EOQzrkLJha8NZwrMmhsXy5OU9GHcS2Q9AGWPGmR91BuMjn-c6rR8pIOp2CFdti3UClnBMbLi2FT8p93PNgn4nWf7q6Nsd7rda__bM7pOrpY-NX1dGMEmWdPpDbJZolZOn5fU2i9uki8dwHrEeBDvoL5n3z597oIRrrSiB2diOqU7HxeZwM8ZmJ9L3-rc5g3SkU1b1HS8PJtltIdVNZpCGIKHjTQ5p4fzTE9sK7R0QkddGLbvwVhlmnFKT9Pir3Chsgi45UBgB7UTwPT8Fjm8kGd0mzTSWarvEmpcYULlaRN4ItChTBLDwwSCTeFGgrdlkziV1sSypG7HDiLTuCCdZjFqWVxrWZM8q-XnBWnJHyXfoBLWUkg2bn-YZZO4xK5YaVcFidE-R3LDiMEaGZpxy9PCeFo1yValjnGJgHCLWheb5HF9GbAL36BI9WxpZSBahRgC5nGnUP16Jn4LmZGYD2u3tvCPhcTgxR34AC_3_j6ZR-TK3njQj_u94f59ssGwmMVmFG6RxiJb6gfkslwtTvPsYWnalLy7aEv5DrEEji4
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VghAXoLwaKLBIIOBgxV476-SAECSNiFpCpLaoN7PenU0rpU5wHtAbP4EzP4Wfwy9hZv0AJB6nHrjGm_WuPd881jPfMPZQGmF9K7Qn00B4VFrppW2jPa1E1AojGRmIXLOJeDhsHx52Rmvsa1ULQ2mVlU50itpMNZ2RN9FwC9mJ0Vtv2jItYtTrP5-996iDFH1prdppFCKyA6cfMHybPxv08F0_EqK_vd995ZUdBjxNhhp1kMVFhSqQKgp8EKn1A4BUibRj2xH6Nkr5GPALaWItVQhWCoMQl9anUiWjQ5z3HDsfR2iUKW1QvPlxvtMKiRim4on0RVOZFfGDU4wlqb34T3bQtQv4nY_7q8vsbF7_yv_8tK6yy6WnzV8U0Nhga5BdYxulLpvzJyXh9tPr7EsXLQBpfhzeJRTk3z597iE0V2D43omaTPj2x0Wu6CMHZe3ytzB32YR85JIZge8vT6Y5H1CtDXAMTugIkqen_GCWw9g1SMvGfNTDaXcDnKtMPs74cVb8FS9UOMFbvlbUV-0INf38Bjs4k2d0k61n0ww2Gbe-srEJwEaBiiDWaWplnGIIqvy2kh3dYF4lQYkuCd2pr8gkKaioRUISl9QS12CP6_GzgsrkjyNfkkDWo4iC3P0wzcdJqdESA76JUguhJMrDtsA9CgJ3KwBlAzANtlWJZlLqRbxFLZcN9qC-jBqN3qDKYLp0YzCGxcgC13GrgEG9krBFfEkixL07XPxjIwn6dnshKp3bf1_MfXYR4ZHsDoY7d9glQRUuLs1wi60v8iXcZRf0anE8z-85jHP27qxh8h1yEJVo
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Colorectal+Cancer-Derived+Small+Extracellular+Vesicles+Promote+Tumor+Immune+Evasion+by+Upregulating+PD-L1+Expression+in+Tumor-Associated+Macrophages&rft.jtitle=Advanced+science&rft.au=Yin%2C+Yuan&rft.au=Liu%2C+Bingxin&rft.au=Cao%2C+Yulin&rft.au=Yao%2C+Surui&rft.date=2022-03-01&rft.eissn=2198-3844&rft.volume=9&rft.issue=9&rft.spage=e2102620&rft_id=info:doi/10.1002%2Fadvs.202102620&rft_id=info%3Apmid%2F35037423&rft.externalDocID=35037423
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2198-3844&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2198-3844&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2198-3844&client=summon